Home > Insider Trading > Filing (0000899243-19-022590)

Filing Details

Accession Number:: 0000899243-19-022590
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-08-29 19:56:38
Reporting Period:: 2019-08-27

Accepted Time:: 2019-08-29 19:56:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1438133	Tandem Diabetes Care Inc	TNDM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1270735	A Douglas Roeder	C/O Delphi Ventures, 63 Bovet Road, Suite 351 San Mateo CA 94402		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-08-27	122,018	$70.10	1,173,628	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-27	1,191	$70.10	11,460	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-28	166,704	$70.42	1,006,924	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-28	1,628	$70.42	9,832	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-28	16,594	$71.00	990,330	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-08-28	162	$71.00	9,670	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.
This transaction was executed in multiple trades at prices ranging from $70.00 to $70.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $70.00 to $70.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $71.00 to $71.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.